Literature DB >> 11073754

Susceptibility testing for mycobacteria.

G L Woods1.   

Abstract

Mycobacterial susceptibility testing is important for the management of patients with tuberculosis and those with disease caused by certain nontuberculous mycobacteria. To help standardize methods used in the clinical microbiology laboratory for testing susceptibility of mycobacteria, the National Committee for Clinical Laboratory Standards (NCCLS) recently updated NCCLS document M24-T (published in 1995), which is the tentative standard for antimycobacterial susceptibility testing of Mycobacterium tuberculosis. The second edition of the NCCLS tentative standard (document M24-T2) differs considerably from the initial document. It contains revised guidelines for the testing of M. tuberculosis complex and newly proposed guidelines for the testing of some nontuberculous mycobacteria, including the rapidly growing mycobacteria (Mycobacterium fortuitum group, Mycobacterium chelonae, and Mycobacterium abscessus), Mycobacterium avium complex, Mycobacterium kansasii, and Mycobacterium marinum, as well as Nocardia species and other aerobic actinomycetes. The recommendations for mycobacterial susceptibility testing that are outlined in NCCLS document M24-T2 are reviewed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073754     DOI: 10.1086/317441

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  46 in total

1.  Soft tissue infection caused by a novel pigmented, rapidly growing mycobacterium species.

Authors:  Christine Y Turenne; Amar A Suchak; Joyce N Wolfe; Amin Kabani; Lindsay E Nicolle
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

2.  Kothari et al.: "An unusual cause of stridor: retropharyngeal cold abscess".

Authors:  Hasan Yasan; Harun Doğru
Journal:  Pediatr Surg Int       Date:  2003-12-24       Impact factor: 1.827

3.  Comparison of flow cytometric and Alamar Blue tests with the proportional method for testing susceptibility of Mycobacterium tuberculosis to rifampin and isoniazid.

Authors:  Roberto S Reis; Ivan Neves; Sergio L S Lourenço; Leila S Fonseca; Maria Cristina S Lourenço
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

4.  Mycobacterium reverse hybridization line-probe assay used to diagnose disseminated Mycobacterium haemophilum infection in a child with acute lymphoblastic leukemia.

Authors:  F Bosma; J M Deckers-Kocken; S S N de Graaf; T Schülin; W J G Melchers; J A Hoogkamp-Korstanje
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-06       Impact factor: 3.267

5.  Double recombinant Mycobacterium bovis BCG strain for screening of primary and rationale-based antimycobacterial compounds.

Authors:  Vandana Singh; Rajesh Kumar Biswas; Bhupendra N Singh
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

6.  Drug-resistant tuberculosis in sub-saharan Africa.

Authors:  Jeffrey Hafkin; Victoria M Gammino; Joseph J Amon
Journal:  Curr Infect Dis Rep       Date:  2010-01       Impact factor: 3.725

7.  First case of Segniliparus rotundus pneumonia in a patient with bronchiectasis.

Authors:  Won-Jung Koh; Go-Eun Choi; Seung-Heon Lee; Young Kil Park; Nam Yong Lee; Sung Jae Shin
Journal:  J Clin Microbiol       Date:  2011-07-13       Impact factor: 5.948

8.  Mycobacterium neoaurum bacteremia in a hemodialysis patient.

Authors:  Marissa L Becker; Amar A Suchak; Joyce N Wolfe; Ryan Zarychanski; Amin Kabani; Lindsay E Nicolle
Journal:  Can J Infect Dis       Date:  2003-01

9.  Evaluation of the broth microdilution method using 2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride for rapidly growing mycobacteria susceptibility testing.

Authors:  Sun Min Lee; Jeong man Kim; Joseph Jeong; Young Kil Park; Gill-Han Bai; Eun Yup Lee; Min Ki Lee; Chulhun L Chang
Journal:  J Korean Med Sci       Date:  2007-10       Impact factor: 2.153

10.  Tuberculosis disparity between US-born blacks and whites, Houston, Texas, USA.

Authors:  Jose A Serpa; Larry D Teeter; James M Musser; Edward A Graviss
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.